Is Abbott trying to buy its way back into the drug biz?

Abbott Laboratories ($ABT) has largely focused on medical devices and diagnostics since spinning its innovative drugs business off into AbbVie ($ABBV), but Reuters reports the company is bidding on Brazilian drugmaker Aché Laboratorios Farmaceuticos, which could be worth up to $5 billion. Abbott joins Pfizer ($PFE) and Novartis ($NVS) in the running to acquire the privately held company, Reuters' sources say, but the deal could stall if one of the controlling families declines to sell its stake. Report | More

Suggested Articles

The former Fierce 15 winner’s SuperMap program was cleared to guide electrophysiologists in the treatment of stable and transient arrhythmias.

Insulet announced new agreements with Abbott and Dexcom to connect their continuous glucose monitors with its upcoming tubeless, digital insulin pump,

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.